<DOC>
	<DOCNO>NCT00088140</DOCNO>
	<brief_summary>The purpose study determine IDN-6556 , give orally , safe effective patient chronic hepatitis C virus infection .</brief_summary>
	<brief_title>A Caspase Inhibitor Chronic Hepatitis C ( HCV ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Caspase Inhibitors</mesh_term>
	<criteria>Chronic hepatitis C infection Unsuccessful prior HCV treatment Liver impairment ( either AST ALT 1.510.0 x ULN ) Alphafetoprotein &lt; = 50 ng/mL Adequate hematologic parameter Decompensated severe liver disease Hepatocellular carcinoma HIV infection Coinfection hepatitis B virus ( HBV ) Renal impairment Pancreatitis Use illicit drug abuse History alcohol abuse Presence clinically significant cardiac arrhythmia If female , pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>